Tony Robbins

The Celebrity Play

Author and investor, Fountain Life (co-founder); CMS lists no organization

Wellness / Longevity Biotech· Member, confirmed on the Nov. 9, 2026 agenda

Last verified November 6, 2026

Overview

Motivational speaker turned longevity investor. Co-founder of Fountain Life ($21,500-a-year subscription diagnostics, $108 million raised) and investor in Celularity, a stem cell company, according to his own book and press coverage. Co-authored "Life Force" with his business partners, a #1 New York Times bestseller that promoted companies he owns. Appeared at a CMS quality conference, reportedly impressing Oz enough to earn a seat. He was the only member absent from the committee's first meeting in May 2026 and was sworn in the next day. In June 2026 Celularity and Fountain Life began offering an FDA-unapproved placental cell therapy to Florida physicians under a 2025 state law. Celularity's June 30 quarterly report showed $586,000 in cash and substantial doubt about its ability to continue, followed by a recapitalization in September. Senators Wyden and Merkley called him a motivational speaker with no healthcare credentials.

Since March 2026

What has changed

April 13, 2026Press release distributed via PRUnderground announced his appointment, calling him a peak performance coach and philanthropist; he said the effort would 'transcend politics.' No companies named. source
May 18, 2026Did not attend the inaugural HAC meeting (the only member absent). CMS told a questioner he remains a member and was sworn in the following day, May 19. source
June 4, 2026Celularity and Fountain Life announced cenplacel-L, an FDA-unapproved placental cell therapy, available for investigational use by licensed Florida physicians under a 2025 Florida law. Release names Robbins a Fountain Life co-founder. source
June 9, 2026Celularity (Fountain Life partner; Robbins described as investor) received Nasdaq notices: June 9 market value below $35M; July 23 bid price below $1; Aug 21 late 10-Q. Nasdaq confirmed Sept 11 it regained the first two. source
July 14, 2026Sens. Wyden and Merkley's letter to Kennedy and Oz described Robbins as a motivational speaker with no healthcare credentials who skipped the committee's first meeting. source
July 14, 2026STAT: the senators' letter raised 'serious concerns' about member credibility and conflicts; Robbins is the one member STAT names. source
August 1, 2026Public Citizen column said Robbins profits from expensive, unproven supplements, has no qualifying credentials, and was reportedly approached by Kennedy as a 2024 running mate. source
September 24, 2026Celularity's 10-Q for the quarter ended June 30, 2026: cash $586K, working capital deficit $53.3M, substantial doubt about going concern; Sept 24 initial closing of $8.8M net from senior secured convertible notes, part of up to $25M recapitalization. source
September 29, 2026Celularity preliminary proxy: Sept 23, 2026 securities purchase agreement with the Philip & Daniele Barach Family Trust; Barach joined the board and Naveen Jain was designated to succeed director Diane Parks. source

Career arc

Professional timeline

Current

Co-Founder & board member

Fountain Life

Investor

Celularity

Author

"Life Force" (2022), "Money: Master the Game," etc.

Motivational speaker / seminar empire

140+ privately held businesses, combined sales exceeding $7B annually

Business interests and affiliations

•Fountain Life: AI-powered longevity/diagnostics, $21,500/year subscription, six centers, $108M raised (Series A + B), co-founded with Peter Diamandis and Dr. Robert Hariri.
•Celularity: stem cell therapeutics, $250M raised, founded by Hariri.
•"Life Force" (2022) #1 NYT bestseller: co-authored with Diamandis and Hariri. Promotes companies Robbins is invested in.
•Hosted Trump "Making America Healthy Again" town hall (October 2024).
•RFK Jr. approached Robbins twice as potential VP running mate. Robbins declined.

Red flags

Conflicts and concerns

Zero healthcare policy expertise. No medical degree, no policy credentials, no operational healthcare experience. Qualification is celebrity, wealth, and political access.

Direct commercial conflict: if committee recommends CMS coverage for precision diagnostics, longevity screening, or regenerative medicine, Robbins' companies benefit directly.

"Life Force" is effectively a 400-page advertisement for companies Robbins owns. Co-authors are his business partners.

Celularity and Fountain Life sell an FDA-unapproved cell therapy in Florida under a state pathway; Celularity reported going-concern doubt in 2026.

Health policy community reaction to his appointment: "somewhere between confusion and amusement."

Physician-owned hospitals

No connection to physician ownership whatsoever. Robbins' commercial interests are in direct-pay longevity and diagnostics: a market that benefits from CMS coverage expansion but has nothing to do with the physician-owned hospital question.

Sources